Marine Antitumor Drugs: Status, Shortfalls and Strategies

被引:92
作者
Bhatnagar, Ira [1 ]
Kim, Se-Kwon [1 ,2 ]
机构
[1] Pukyong Natl Univ, Dept Chem, Pusan 608737, South Korea
[2] Pukyong Natl Univ, Marine Bioproc Res Ctr, Pusan 608737, South Korea
关键词
marine antitumor compounds; cancer signaling pathways; shortfalls in cancer research; clinical status of antitumor drugs; NF-KAPPA-B; FACTOR-I ACTIVATION; HUMAN FIBROSARCOMA CELLS; NATURAL-PRODUCTS; MATRIX METALLOPROTEINASES; A-C; HYPOXIA; INHIBITORS; AGENTS; ACTINOMYCETE;
D O I
10.3390/md8102702
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cancer is considered as one of the deadliest diseases in the medical field. Apart from the preventive therapies, it is important to find a curative measure which holds no loopholes and acts accurately and precisely to curb cancer. Over the past few decades, there have been advances in this field and there are many antitumor compounds available on the market, which are of natural as well as synthetic origin. Marine chemotherapy is well recognized nowadays and profound development has been achieved by researchers to deal with different molecular pathways of tumors. However, the marine environment has been less explored for the production of safe and novel antitumor compounds. The reason is a number of shortfalls in this field. Though ample reviews cover the importance and applications of various anticancerous compounds from marine natural products, in the present review, we have tried to bring the current status of antitumor research based on marine inhibitors of cancer signaling pathways. In addition, focus has been placed on the shortfalls and probable strategies in the arena of marine antitumor drug discovery.
引用
收藏
页码:2702 / 2720
页数:19
相关论文
共 87 条
[1]   Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors [J].
Andersen, Jannik N. ;
Sathyanarayanan, Sriram ;
Di Bacco, Alessandra ;
Chi, An ;
Zhang, Theresa ;
Chen, Albert H. ;
Dolinski, Brian ;
Kraus, Manfred ;
Roberts, Brian ;
Arthur, William ;
Klinghoffer, Rich A. ;
Gargano, Diana ;
Li, Lixia ;
Feldman, Igor ;
Lynch, Bethany ;
Rush, John ;
Hendrickson, Ronald C. ;
Blume-Jensen, Peter ;
Paweletz, Cloud P. .
SCIENCE TRANSLATIONAL MEDICINE, 2010, 2 (43)
[2]   Kendarimide A, a novel peptide reversing P-glycoprotein-mediated multidrug resistance in tumor cells, from a marine sponge of Haliclona sp. [J].
Aoki, S ;
Cao, LW ;
Matsui, K ;
Rachmat, R ;
Akiyama, S ;
Kobayashi, M .
TETRAHEDRON, 2004, 60 (33) :7053-7059
[3]   Daryamides A-C, weakly cytotoxic polyketides from a marine-derived actinomycete of the genus Streptomyces strain CNQ-085 [J].
Asolkar, Ratnakar N. ;
Jensen, Paul R. ;
Kauffman, Christopher A. ;
Fenical, William .
JOURNAL OF NATURAL PRODUCTS, 2006, 69 (12) :1756-1759
[4]   Arenamides A-C, Cytotoxic NFκB Inhibitors from the Marine Actinomycete Salinispora arenicola [J].
Asolkar, Ratnakar N. ;
Freel, Kelle C. ;
Jensen, Paul R. ;
Fenical, William ;
Kondratyuk, Tamara P. ;
Park, Eun-Jung ;
Pezzuto, John M. .
JOURNAL OF NATURAL PRODUCTS, 2009, 72 (03) :396-402
[5]   The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683
[6]   Sansalvamide: A new cytotoxic cyclic depsipeptide produced by a marine fungus of the genus Fusarium [J].
Belofsky, GN ;
Jensen, PR ;
Fenical, W .
TETRAHEDRON LETTERS, 1999, 40 (15) :2913-2916
[7]   The current status of natural products from marine fungi and their potential as anti-infective agents [J].
Bhadury, Punyasloke ;
Mohammad, Balsam T. ;
Wright, Phillip C. .
JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY, 2006, 33 (05) :325-337
[8]  
BONNARD I, 1995, ANTI-CANCER DRUG DES, V10, P333
[9]   Matrix metalloprotease inhibitors: design from structure [J].
Borkakoti, N .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2004, 32 :17-20
[10]  
Bringmann G, 2007, MAR DRUGS, V5, P23, DOI 10.3390/md502023